Covid19 Clinical Trial
Official title:
Advancing DSME/S and COVID-19 Prevention and Protection Through "emPOWERed to Change" Program
Verified date | February 2023 |
Source | Charles Drew University of Medicine and Science |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
African Americans (AA)/People of Color (POC) are disproportionately impacted by COVID-19 to an extent not observed in other racial/ethnic subgroups. People of color are uniquely affected because keeping diabetes under control - the best defense against COVID-19 - has become more difficult as the pandemic has disrupted medical care, exercise and healthy eating routines which are already well-known challenges for the African American community. Diabetes Self-Management Education and Support (DSMS/S) facilitates the knowledge, skills, and ability necessary for diabetes self-care as well as activities that assist a person in implementing and sustaining the behaviors needed to manage their condition on an ongoing basis. Now, given the implications of COVID-19 on the AA/POC diabetes community, it is imperative to enhance DSME/S with education about protection and prevention of COVID-19. To begin to solve this problem we will adapt and implement the "emPOWERed to Change" DSME/S program to provide enhanced type 2 diabetes mellitus (T2DM) education with an additional emphasis on COVID-19 protection and prevention. This study will employ Community Based Participatory Research methods and will be conducted virtually in the community setting. The proposed hypothesis, based on the Health Belief Model (HBM) and the Theory of Planned Behavior (TPB), is: African Americans (AA)/People of Color (POC) in Los Angeles County with type 2 diabetes mellitus (T2DM) randomized to participate in the "emPOWERed to Change" program (N=48) are more likely to demonstrate sustained glycemic control, increase in knowledge and skills related behaviors, and risk factors associated with T2DM and SARS-CoV-2 (COVID-19) and increased compliance with prevention, and vaccination as compared to those who are randomized to usual care (N=48) in this 12 week program. We propose a randomized control study design among 96 participants with 48 assigned to an intervention group and 48 assigned to a control group. This study will also explore the experience of the participants' appraisal of knowledge and skills acquisition for DSME/S to maintain T2DM control, reduce complications, and SARS-CoV-2 (COVID-19) prevention and protection. The ultimate goal is to design prospective larger behavioral studies (SuRe first or R21) with a multi-centered intervention with other RTRN institutions to demonstrate the applicability of this approach specifically focusing on the AA/POC community.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 28, 2023 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 and older African American, Male or Female, must be diagnosed with type 2 diabetes mellitus and be from MLK-OPC, no prior formal DSME/S program participation and must have internet access Exclusion Criteria: - Under 18 years of age, POC but not African American, not diagnosed with type 2 diabetes mellitus, not a patient of LAC DHS MLK-OPC facilities, not having internet access, had or receiving formal DSME/S program |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Charles Drew University of Medicine and Science |
Abazari P, Vanaki Z, Mohammadi E, Amini M. Inadequate investment on management of diabetes education. J Res Med Sci. 2012 Aug;17(8):792-8. — View Citation
Azar KMJ, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, Brown S, Pressman AR. Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. Health Aff (Millwood). 2020 Jul;39(7):1253-1262. doi: 10.1377/hlthaff.2020.00598. Epub 2020 May 21. — View Citation
Cooper, A., & Kar, P. (2014). A new dawn: The role of social media in diabetes education. Journal of Diabetes Nursing, 18(2), 68-71
Cyrus E, Clarke R, Hadley D, Bursac Z, Trepka MJ, Devieux JG, Bagci U, Furr-Holden D, Coudray M, Mariano Y, Kiplagat S, Noel I, Ravelo G, Paley M, Wagner EF. The Impact of COVID-19 on African American Communities in the United States. Health Equity. 2020 Oct 30;4(1):476-483. doi: 10.1089/heq.2020.0030. eCollection 2020. — View Citation
Gabarron E, Arsand E, Wynn R. Social Media Use in Interventions for Diabetes: Rapid Evidence-Based Review. J Med Internet Res. 2018 Aug 10;20(8):e10303. doi: 10.2196/10303. — View Citation
Hernández SR , C. K . COVID-19: a perfect storm of health care inequality. Oakland (CA): California Health Care Foundation; 2020 Apr 10 [cited 2021 May 31]. From: https://www.chcf.org/blog/covid-19-perfect-storm-health-care-inequality/
Kenny, C. (2014). Information technology, education and diabetes. Diabetes & Primary Care, 16(3), p. 111-112.
Kitsiou S, Pare G, Jaana M, Gerber B. Effectiveness of mHealth interventions for patients with diabetes: An overview of systematic reviews. PLoS One. 2017 Mar 1;12(3):e0173160. doi: 10.1371/journal.pone.0173160. eCollection 2017. — View Citation
Los Angeles County Department of Public Health. COVID-19 racial, ethnic, and socioeconomic data and strategies report [Internet]. Los Angeles (CA): LA County Department of Public Health; 2020 Apr 28 [cited 2021 May 31]. http://www.lapublichealth.org/docs/RacialEthnicSocioeconomicDataCOVID19.pdf
McMahon, K. L. (2013). Power and Pitfalls of Social Media in Diabetes Care. Diabetes Spectrum, 26(4), 232-235. doi:10.2337/diaspect.26.4.232
Park S, Burford S, Nolan C, Hanlen L. The Role of Digital Engagement in the Self-Management of Type 2 Diabetes. Health Commun. 2016 Dec;31(12):1557-65. doi: 10.1080/10410236.2015.1089468. Epub 2016 Apr 28. — View Citation
Public Policy Institute of California (2021). California's Digital Divide. https://www.ppic.org/publication/californias-digital-divide/
Snowden LR, Graaf G. COVID-19, Social Determinants Past, Present, and Future, and African Americans' Health. J Racial Ethn Health Disparities. 2021 Feb;8(1):12-20. doi: 10.1007/s40615-020-00923-3. Epub 2020 Nov 23. — View Citation
Torres, E. A., Tiwari, A., Movsas, S., Carrasquillo, I., & Zonszein, J. (2015). Underutilization of Diabetes Education. Experience in an Urban Teaching Hospital in The Bronx. J Diabetes Metab Syndr Disord, 2(005).
Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, Chen L, Han D, Fan Y, Zeng Y, Li W, Lin F, Li S, Chen X, Pan P; medical team from Xiangya Hospital to support Hubei, China. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study. Diabetes Res Clin Pract. 2020 Jul;165:108227. doi: 10.1016/j.diabres.2020.108227. Epub 2020 May 22. — View Citation
* Note: There are 15 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Type 2 Glycemic Control - HbA1c of 7% or less | Achieve Glycemic control defined as an HbA1c of 7% or less | 12 weeks | |
Secondary | Understanding of Diabetes Self-Management | Exhibit increased knowledge and skills as it relates to eating habits, physical activity, stress management, and medication adherence as measured by the DSMQ | 12 weeks | |
Secondary | Understand of COVID-19 Risks, Protection and Prevention | Exhibit increased knowledge related to risk factors associated with T2DM and COVID-19, prevention of infection, available resources and COVID-19 vaccines, and access resources for vaccination | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |